Navigation Links
iCAD Completes Acquisition of CAD Sciences
Date:7/21/2008

NASHUA, N.H., July 21 /PRNewswire-FirstCall/ -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of Computer-Aided Detection (CAD) solutions, today announced the completion of its previously announced agreement to purchase the principal assets of CAD Sciences, a privately-held medical technology company based in White Plains, NY. The purchase price was $5 million, comprised of $2 million in cash and 1,086,957 shares of iCAD common stock. The number of shares issued was calculated using the average closing price for the 10 consecutive trading days immediately preceding the closing.

"iCAD's acquisition of CAD Sciences broadens our leadership position beyond mammography CAD and provides a comprehensive portfolio of advanced image analysis and workflow solutions for the early detection of the most prevalent cancers. Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) are demonstrating significant advances in the imaging sector and this acquisition now extends our reach in the imaging modalities of CT and MRI, in addition to our expertise in film-based, digital radiography and computed radiography," commented Ken Ferry, President and CEO of iCAD.

"Our integration of this leading CAD technology for breast and prostate MRI should provide significant synergy regarding customer call points for our sales team, and we expect physician adoption to be accelerated by iCAD's strong market position in mammography CAD," he added.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by more than 2,200 women's healthcare centers worldwide. For more information, call +1 877 iCADnow or visit http://www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward- looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.

For iCAD, contact Darlene Deptula-Hicks at 603-882-5200 x7944, or via email at ddeptula@icadmed.com

For Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn & Associates at 212-838-3777 x6604 or via email at afields@lhai.com

For Public Relations, contact Jill Testagrossa of Schwartz Communications at 781-684-0770 or via e-mail at icad@schwartz-pr.com


'/>"/>
SOURCE iCAD, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
4. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
5. GSI Securitization Completes Merger and Domicile Transfer
6. Medical Services International Inc. Completes Testing for European Union (EU) Application
7. Inverness Completes Acquisition of Cholestech
8. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
9. Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants
10. Explorer completes the map ... for the bodys blueprint
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... ... i2i Population Health, a national leader in population health management (PHM) technology, ... financial background is an excellent fit for i2i,” says Justin Neece, president. “He’s that ... need to take the company to the next level of growth.” , McNamara ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... advance to the semi-final round of the 2017 Cupid's Cup Entrepreneurship Competition. Chaired ... its 12th year in 2017. The entrepreneurs will showcase their businesses on February ...
(Date:1/24/2017)... Philadelphia, PA (PRWEB) , ... January 24, 2017 , ... ... America, but the co-founder of the organization End Distracted Driving , Joel Feldman, ... Today. , Feldman's story was featured in one of the top newspapers in circulation ...
(Date:1/24/2017)... ... January 24, 2017 , ... Providing solutions to critical economic ... the Frank Hawkins Kenan Institute of Private Enterprise at the University ... makers identified concrete solutions at the “What’s Next, America?” conference at the Kenan ...
(Date:1/24/2017)... ... 24, 2017 , ... The NewKILO JRP, a three-year project of the European ... European Union (EU), was completed in May 2015. The future definition will require the ... in air, which presents some challenges to establishing traceability to the mass scale. , ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... Md. , and GAITHERSBURG, Md. , ... XON ), a leader in the engineering and industrialization ... of the planet, today announced that it has entered into ... GNVC ), a clinical-stage company and pioneer in ... Intrexon intends to integrate and expand upon GenVec,s expertise in ...
(Date:1/24/2017)... PUNE, India , January 24, 2017 ... "Acidity Regulators Market - Global Opportunity Analysis and Industry ... valued at $4,456 million in 2015, and is expected to reach ... 2016 to 2022. Asia-Pacific generated the highest ... by North America and Europe ...
(Date:1/24/2017)... Jan. 24, 2017 Mezzion has filed a ... State court alleging that Dr. Reddy,s committed fraud relating ... and Drug Administration (FDA) cGMP practices, and misrepresenting its ... repeatedly represented to Mezzion that it was compliant with ... Mezzion.  The suit also states that Dr. Reddy,s misconduct ...
Breaking Medicine Technology: